Epigenetics: A novel therapeutic approach for the treatment of Alzheimer's disease
Open accessThe DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) is the most common type of dementia in the elderly. It is characterized by the deposition of two forms of aggregates within the brain, the amyloid β plaques and tau neurofibrillary tangles. Currently, no disease-modifying agent is approved for the treatment of AD. Approved pharmacotherapies target the peripheral symptoms but they do not prevent or slow down the progression of the disease. Although several disease-modifying immunotherapeutic agents are in clinical development, many have failed due to lack of efficacy or serious adverse events. Epigenetic changes including DNA methylation and histone modifications are involved in learning and memory and have been recently highlighted for holding promise as potential targets for AD therapeutics. Dynamic and latent epigenetic alterations are incorporated in AD pathological pathways and present valuable reversible targets for AD and other neurological disorders. The approval of epigenetic drugs for cancer treatment has opened the door for the development of epigenetic drugs for other disorders including neurodegenerative diseases. In particular, methyl donors and histone deacetylase inhibitors are being investigated for possible therapeutic effects to rescue memory and cognitive decline found in such disorders. This review explores the area of epigenetics for potential AD interventions and presents the most recent findings in this field.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484 · cited 8×
“NFTs are composed of tau protein which belongs to a family of microtubule-associated proteins that normally promote microtubule assembly (Weingarten et al., 1975).”
InfluentialSperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155 · cited 2×
“The use of epigenetics will likely be evenmore crucial as the field moves towards early and pre-symptomatic case detection and earlier attempts at intervention (Sperling et al., 2011).”
Jaenisch, R., & Bird, A. (2003) · Nature Genetics · doi:10.1038/ng1089 · Cited by 6,325
Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2
Amir, R. E., Van den Veyver, I. B., Wan, M., Tran, C. Q., Francke, U., & Zoghbi, H. Y. (1999) · Nature Genetics · doi:10.1038/13810 · Cited by 4,990
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659 · cited 1×
“Only about 5% of cases are familial or early onset ADwhich is associatedwith rare mutations on the APP, PS1 and PS2 genes (Goate et al., 1991; Sherrington et al., 1995; Tanzi, 2012).”
Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051 · cited 1×
“Only about 5% of cases are familial or early onset ADwhich is associatedwith rare mutations on the APP, PS1 and PS2 genes (Goate et al., 1991; Sherrington et al., 1995; Tanzi, 2012).”
CpG-rich islands and the function of DNA methylation
Bird, A. P. (1986) · Nature · doi:10.1038/321209a0 · Cited by 3,777 · cited 1×
“DNA methylation occurs on the 5′ position of cytosine in CpG rich regions (Bird, 1986).”
Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17
Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., Pickering-Brown, S., Chakraverty, S., Isaacs, A., Grover, A., et al. (1998) · Nature · doi:10.1038/31508 · Cited by 3,498
Plasma Homocysteine as a Risk Factor for Dementia and Alzheimer's Disease
Seshadri, S., Beiser, A., Selhub, J., Jacques, P. F., Rosenberg, I. H., D'Agostino, R. B., Wilson, P. W. F., & Wolf, P. A. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011613 · Cited by 3,237 · cited 2×
“…and the lack of a placebo-treated control group suggest that further trials are needed to properly evaluate betaine's efficacy in AD (Knopman & Patterson, 2001), especially that elevated homocysteine has been associated with dementia and AD and betaine lowers homocysteine (Seshadri et al., 2002).”
A protein factor essential for microtubule assembly
Weingarten, M. D., Lockwood, A. H., Hwo, S. Y., & Kirschner, M. W. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.5.1858 · Cited by 3,089
Bird, A. (2007) · Nature · doi:10.1038/nature05913 · Cited by 3,011
Genomic DNA methylation: the mark and its mediators.
Klose, R. J., & Bird, A. P. (2006) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2005.12.008 · Cited by 2,501 · cited 1×
“There are multiple ways for targeting DNA methylation for therapeutic purposes (Klose & Bird, 2006).”
Lee, V. M.-Y., Goedert, M., & Trojanowski, J. Q. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.1121 · Cited by 2,480 · cited 3×
“…with neurodegeneration and memory decline and have been extensively targeted for AD interventions such as immunotherapeutics, enzyme modulators, and aggregation inhibitors (Hardy & Higgins, 1992; Selkoe, 1993; Hutton et al., 1998; Lee et al., 2001; Hardy & Selkoe, 2002; Iqbal et al., 2009).”
Yang, F., Lim, G. P., Begum, A. N., Ubeda, O. J., Simmons, M. R., Ambegaokar, S. S., Chen, P. P., Kayed, R., Glabe, C. G., Frautschy, S. A., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m404751200 · Cited by 2,336 · cited 1×
“While in transgenic animal models, curcumin decreased oxidative damage and Aβ pathology by affecting anti-inflammatory pathways (Lim et al., 2001; Yang et al., 2005; Begum et al., 2008; Hamaguchi et al., 2010).”
MeCP2, a Key Contributor to Neurological Disease, Activates and Represses Transcription
Chahrour, M., Jung, S. Y., Shaw, C., Zhou, X., Wong, S. T. C., Qin, J., & Zoghbi, H. Y. (2008) · Science · doi:10.1126/science.1153252 · Cited by 1,823
Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein
De Strooper, B., Saftig, P., Craessaerts, K., Vanderstichele, H., Guhde, G., Annaert, W., Von Figura, K., & Van Leuven, F. (1998) · Nature · doi:10.1038/34910 · Cited by 1,818 · cited 2×
“In addition, neurons lacking the PS1 gene fail to produce Aβ peptides (De Strooper et al., 1998; Naruse et al., 1998).”
Alzheimer Mechanisms and Therapeutic Strategies
Huang, Y., & Mucke, L. (2012) · Cell · doi:10.1016/j.cell.2012.02.040 · Cited by 1,758 · cited 1×
“With the increase in life expectancy and the absence of disease-modifying agents, the number of people with AD is expected to triple within the upcoming 40 years (Barnes & Yaffe, 2011; Huang & Mucke, 2012; Tricco et al., 2012).”
Phiel, C. J., Zhang, F., Huang, E. Y., Guenther, M. G., Lazar, M. A., & Klein, P. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101287200 · Cited by 1,758 · cited 1×
“Valproic acid, which is used as an anticonvulsant in epileptic patients and as a mood stabilizer in bipolar disorder patients (Phiel et al., 2001), is a known HDAC inhibitor and has therefore been proposed for use in cancer and AD (Gottlicher et al., 2001; Kramer et al., 2003; Nalivaeva et al.,…”
HDAC2 negatively regulates memory formation and synaptic plasticity
Guan, J.-S., Haggarty, S. J., Giacometti, E., Dannenberg, J.-H., Joseph, N., Gao, J., Nieland, T. J. F., Zhou, Y., Wang, X., Mazitschek, R., et al. (2009) · Nature · doi:10.1038/nature07925 · Cited by 1,644 · cited 3×
“Overexpression of HDAC2 and not HDAC1, both Class I HDACs, in mice impairs memory and the chronic administration of the HDAC inhibitors vorinostat or sodium butyrate enhances cognition (Guan et al., 2009).”
Histone deacetylase inhibitors: molecular mechanisms of action
Xu, W. S., Parmigiani, R. B., & Marks, P. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210620 · Cited by 1,542 · cited 1×
“There are 18 HDACs identified that belong to four classes I, II, III and IV according to their sequence homology (Xu et al., 2007).”
Lim, G. P., Chu, T., Yang, F., Beech, W., Frautschy, S. A., & Cole, G. M. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-21-08370.2001 · Cited by 1,530
Histone-deacetylase inhibitors: novel drugs for the treatment of cancer
Johnstone, R. W. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd772 · Cited by 1,515 · cited 2×
“lung and colon cancer (Johnstone, 2002; Barneda-Zahonero & Parra, 2012; New et al., 2012).”
Silva, A. J., Kogan, J. H., Frankland, P. W., & Kida, S. (1998) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.21.1.127 · Cited by 1,462 · cited 9×
“The rationale behind choosing cilostazol is to promote the phosphorylation of CREB which regulates its activity and consequential expression of genes that are controlled by CREB (Bito et al., 1996; Silva et al., 1998; ClinicalTrials.gov., identifier: NCT01409564, 2011).”
InfluentialProduction of the Alzheimer Amyloid β Protein by Normal Proteolytic Processing
Shoji, M., Golde, T. E., Ghiso, J., Cheung, T. T., Estus, S., Shaffer, L. M., Cai, X.-D., McKay, D. M., Tintner, R., Frangione, B., et al. (1992) · Science · doi:10.1126/science.1439760 · Cited by 1,447 · cited 1×
“Senile plaques are mainly composed of Aβ which is cleaved off the larger amyloid β precursor protein (APP) by β-site APP cleaving enzyme (BACE), also known as β-secretase, and γ-secretase (Shoji et al., 1992; Citron et al., 1995).”
Faghihi, M. A., Modarresi, F., Khalil, A. M., Wood, D. E., Sahagan, B. G., Morgan, T. E., Finch, C. E., St. Laurent III, G., Kenny, P. J., & Wahlestedt, C. (2008) · Nature Medicine · doi:10.1038/nm1784 · Cited by 1,416 · cited 2×
“BACE1-AS is a long non-coding RNA antisense transcript of BACE1 that improves BACE1 stability and expression and is upregulated in the hippocampus and cortex of AD patients (Faghihi et al., 2008).”
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
Mann, B. S., Johnson, J. R., Cohen, M. H., Justice, R., & Pazdur, R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-10-1247 · Cited by 1,365 · cited 2×
“Many HDAC inhibitors are in clinical trials for cancer therapy, vorinostat and romidepsin have been approved by the FDA for cutaneous T-cell lymphoma (Kim et al., 2012; Mann et al., 2007; Nebbioso et al., 2012).”
Epigenetic protein families: a new frontier for drug discovery
Arrowsmith, C. H., Bountra, C., Fish, P. V., Lee, K., & Schapira, M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3674 · Cited by 1,327 · cited 1×
“EVP-0334 is an HDAC inhibitor developed for AD by EnVivo Pharmaceuticals that successfully completedphase I clinical trials andwas deemed safe for further testing, however, detailed information on the trial have not been made available yet (Mack, 2010; Arrowsmith et al., 2012; Caraci et al., 2012).”
Recovery of learning and memory is associated with chromatin remodelling
Fischer, A., Sananbenesi, F., Wang, X., Dobbin, M., & Tsai, L.-H. (2007) · Nature · doi:10.1038/nature05772 · Cited by 1,227 · cited 1×
“HDAC inhibitors show promise for cognitive improvement and are being considered for drug development for AD (Fischer et al., 2007; Abel & Zukin, 2008; Guan et al., 2009).”
Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP
Petrif, F., Giles, R. H., Dauwerse, H. G., Saris, J. J., Hennekam, R. C. M., Masuno, M., Tommerup, N., van Ommen, G.-J. B., Goodman, R. H., Peters, D. J. M., et al. (1995) · Nature · doi:10.1038/376348a0 · Cited by 1,217 · cited 2×
“In humans, mutations on the CBP gene result in Rubinstein-Taybi syndrome which is characterized by mental retardation (Petrij et al., 1995; Rubinstein & Taybi, 1963).”
Hébert, S. S., Horré, K., Nicolaï, L., Papadopoulou, A. S., Mandemakers, W., Silahtaroglu, A. N., Kauppinen, S., Delacourte, A., & De Strooper, B. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710263105 · Cited by 1,183 · cited 2×
“An example is microRNA-101 which negatively regulates APP levels and is reduced within the brain cortex of AD patients (Hebert et al., 2008; Vilardo et al., 2010).”
Regulation of histone acetylation during memory formation in the hippocampus
Levenson, J. M., O'Riordan, K. J., Brown, K. D., Trinh, M. A., Molfese, D. L., & Sweatt, J. D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402229200 · Cited by 1,131 · cited 5×
“pocampal tissues collected 1 h after fear conditioning experiments (Levenson et al., 2004).”
InfluentialKim, D., Nguyen, M. D., Dobbin, M. M., Fischer, A., Sananbenesi, F., Rodgers, J. T., Delalle, I., Baur, J. A., Sui, G., Armour, S. M., et al. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601758 · Cited by 1,074 · cited 2×
“However, resveratrol cognitive benefits involve other mechanisms besides SIRT1 activation and its epigenetic functions (Kim et al., 2007; Huber & Superti-Furga, 2011).”
Craig, S. A. (2004) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/80.3.539 · Cited by 1,062 · cited 1×
“Betaine, the methyl donor used conventionally for homocystinuria treatment (Key, 2000), was tested in 8 AD patients for 24 weeks and failed to demonstrate cognitive improvement (Craig, 2004; Knopman & Patterson, 2001).”
Dnmt1 and Dnmt3a maintain DNA methylation and regulate synaptic function in adult forebrain neurons
Feng, J., Zhou, Y., Campbell, S. L., Le, T., Li, E., Sweatt, J. D., Silva, A. J., & Fan, G. (2010) · Nature Neuroscience · doi:10.1038/nn.2514 · Cited by 1,019
Heim, C., & Binder, E. B. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2011.10.032 · Cited by 986
Acetylation of Tau Inhibits Its Degradation and Contributes to Tauopathy
Min, S.-W., Cho, S.-H., Zhou, Y., Schroeder, S., Haroutunian, V., Seeley, W. W., Huang, E. J., Shen, Y., Masliah, E., Mukherjee, C., et al. (2010) · Neuron · doi:10.1016/j.neuron.2010.08.044 · Cited by 949 · cited 3×
“On the other hand, inhibition of the HAT p300 by using the commercially available p300 inhibitor C646 reduces the levels of acetylated tau and phosphorylated tau at Ser202 in vitro (Min et al., 2010).”
Cogswell, J. P., Ward, J., Taylor, I. A., Waters, M., Shi, Y., Cannon, B., Kelnar, K., Kemppainen, J., Brown, D., Chen, C., et al. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-14103 · Cited by 943 · cited 2×
“Various microRNAs are differentially expressed in AD and alter the expression of AD pathological intermediates (Cogswell et al., 2008; Nunez-Iglesias et al., 2010; Provost, 2010).”
An epigenetic blockade of cognitive functions in the neurodegenerating brain
Gräff, J., Rei, D., Guan, J.-S., Wang, W.-Y., Seo, J., Hennig, K. M., Nieland, T. J. F., Fass, D. M., Kao, P. F., Kahn, M., et al. (2012) · Nature · doi:10.1038/nature10849 · Cited by 853
CBP Histone Acetyltransferase Activity Is a Critical Component of Memory Consolidation
Korzus, E., Rosenfeld, M. G., & Mayford, M. (2004) · Neuron · doi:10.1016/j.neuron.2004.06.002 · Cited by 823 · cited 9×
“The most widely studied histone modification is regulated by two groups of enzymes, histone acetyltransferases (HATs) and histone deacetylases (HDACs).”
InfluentialKilgore, M., Miller, C. A., Fass, D. M., Hennig, K. M., Haggarty, S. J., Sweatt, J. D., & Rumbaugh, G. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.197 · Cited by 727 · cited 4×
“improves memory in the APPswe/PS1dE9 AD mouse model (Kilgore et al., 2010).”
InfluentialThe genetics of Alzheimer disease
Tanzi, R. E. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006296 · Cited by 727
The acetylation of tau inhibits its function and promotes pathological tau aggregation
Cohen, T. J., Guo, J. L., Hurtado, D. E., Kwong, L. K., Mills, I. P., Trojanowski, J. Q., & Lee, V. M. Y. (2011) · Nature Communications · doi:10.1038/ncomms1255 · Cited by 724 · cited 1×
“For example SIRT1 accounts for tau deacetylation which is considered neuroprotective while tau acetylation contributes to tau dysfunction and aggregation (Min et al., 2010; Cohen et al., 2011; Stunkel & Campbell, 2011).”
Mechanisms of tau-induced neurodegeneration
Iqbal, K., Liu, F., Gong, C.-X., Alonso, A. D. C., & Grundke-Iqbal, I. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0486-3 · Cited by 628
Antidepressant Actions of Histone Deacetylase Inhibitors
Covington, H. E., Maze, I., LaPlant, Q. C., Vialou, V. F., Ohnishi, Y. N., Berton, O., Fass, D. M., Renthal, W., Rush, A. J., Wu, E. Y., et al. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.1758-09.2009 · Cited by 624
Reelin and ApoE receptors cooperate to enhance hippocampal synaptic plasticity and learning
Weeber, E. J., Beffert, U., Jones, C., Christian, J. M., Förster, E., Sweatt, J. D., & Herz, J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205147200 · Cited by 623 · cited 1×
“DNMTs regulate methylation within the promoter of reelin, an extracellular glycoprotein that is involved in memory formation in the adult brain (Weeber et al., 2002; Levenson et al., 2006).”
Begum, A. N., Jones, M. R., Lim, G. P., Morihara, T., Kim, P., Heath, D. D., Rock, C. L., Pruitt, M. A., Yang, F., Hudspeth, B., et al. (2008) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.137455 · Cited by 604 · cited 1×
“While in transgenic animal models, curcumin decreased oxidative damage and Aβ pathology by affecting anti-inflammatory pathways (Lim et al., 2001; Yang et al., 2005; Begum et al., 2008; Hamaguchi et al., 2010).”
Antidepressant-Like Effects of the Histone Deacetylase Inhibitor, Sodium Butyrate, in the Mouse
Schroeder, F. A., Lin, C. L., Crusio, W. E., & Akbarian, S. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.06.036 · Cited by 541 · cited 1×
“For example, the HDAC inhibitor sodium butyrate shows antidepressant activity in mice (Schroeder et al., 2007).”
The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2
Krämer, O. H., Zhu, P., Ostendorff, H. P., Golebiewski, M., Tiefenbach, J., Peters, M. A., Brill, B., Groner, B., Bach, I., Heinzel, T., et al. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg315 · Cited by 523 · cited 2×
“…acid, which is used as an anticonvulsant in epileptic patients and as a mood stabilizer in bipolar disorder patients (Phiel et al., 2001), is a known HDAC inhibitor and has therefore been proposed for use in cancer and AD (Gottlicher et al., 2001; Kramer et al., 2003; Nalivaeva et al., 2009).”
REVIEW: Curcumin and Alzheimer’s disease
Hamaguchi, T., Ono, K., & Yamada, M. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00147.x · Cited by 450 · cited 3×
“significant changes between curcumin- and placebo-treated groups (Hamaguchi et al., 2010; Ringman et al., 2012).”
Alonso, A. D. C., Grundke-Iqbal, I., Barra, H. S., & Iqbal, K. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.1.298 · Cited by 437
Ricobaraza, A., Cuadrado-Tejedor, M., Pérez-Mediavilla, A., Frechilla, D., Del Río, J., & García-Osta, A. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.229 · Cited by 423
Green, K. N., Steffan, J. S., Martinez-Coria, H., Sun, X., Schreiber, S. S., Thompson, L. M., & LaFerla, F. M. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3203-08.2008 · Cited by 404 · cited 1×
“Interestingly, the nonselective SIRT inhibitor nicotinamide lowers phosphorylated tau and improves cognition in micedemonstrating that SIRTmodulation involves complexmechanisms (Green et al., 2008; Stunkel & Campbell, 2011).”
Histone deacetylase 6 interacts with the microtubule‐associated protein tau
Ding, H., Dolan, P. J., & Johnson, G. V. W. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05564.x · Cited by 387
Effects of PS1 Deficiency on Membrane Protein Trafficking in Neurons
Naruse, S., Thinakaran, G., Luo, J.-J., Kusiak, J. W., Tomita, T., Iwatsubo, T., Qian, X., Ginty, D. D., Price, D. L., Borchelt, D. R., et al. (1998) · Neuron · doi:10.1016/s0896-6273(00)80637-6 · Cited by 355 · cited 1×
“In addition, neurons lacking the PS1 gene fail to produce Aβ peptides (De Strooper et al., 1998; Naruse et al., 1998).”
microRNA-34c is a novel target to treat dementias
Zovoilis, A., Agbemenyah, H. Y., Agis‐Balboa, R. C., Stilling, R. M., Edbauer, D., Rao, P., Farinelli, L., Delalle, I., Schmitt, A., Falkai, P., et al. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.327 · Cited by 353
Nguyen, A., Rauch, T. A., Pfeifer, G. P., & Hu, V. W. (2010) · The FASEB Journal · doi:10.1096/fj.10-154484 · Cited by 350 · cited 2×
“responses that genetics alone does not completely explain including AD, depression, schizophrenia, glioma, addiction, Rett syndrome, alcohol dependence, autism, epilepsy, multiple sclerosis and stress (Shahbazian & Zoghbi, 2002; Jaenisch & Bird, 2003; Zawia et al., 2009; Nguyen et al., 2010; Qureshi & Mehler, 2010; Ma…”
ERK/MAPK regulates hippocampal histone phosphorylation following contextual fear conditioning
Chwang, W. B., O’Riordan, K. J., Levenson, J. M., & Sweatt, J. D. (2006) · Learning & Memory · doi:10.1101/lm.152906 · Cited by 341
Epigenetics, oxidative stress, and Alzheimer disease
Zawia, N. H., Lahiri, D. K., & Cardozo-Pelaez, F. (2009) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.02.006 · Cited by 337
Self-citationHöller, M., Westin, G., Jiricny, J., & Schaffner, W. (1988) · Genes & Development · doi:10.1101/gad.2.9.1127 · Cited by 305 · cited 1×
“Sp1 is able to bind to CpG sites in gene promoters that have such specific binding motifs and activate their transcription whether they are methylated or non-methylated (Holler et al., 1988).”
REVIEWThe Gene Defects Responsible for Familial Alzheimer's Disease
Tanzi, R. E., Kovacs, D. M., Kim, T.-W., Moir, R. D., Guenette, S. Y., & Wasco, W. (1996) · Neurobiology of Disease · doi:10.1006/nbdi.1996.0016 · Cited by 265
Bakulski, K. M., Dolinoy, D. C., Sartor, M. A., Paulson, H. L., Konen, J. R., Lieberman, A. P., Albin, R. L., Hu, H., & Rozek, L. S. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-111223 · Cited by 255 · cited 2×
“Other studies have demonstrated that there is abnormal methylation in AD patients (Bakulski et al., 2012; Wang et al., 2008a).”
Caccamo, A., Maldonado, M. A., Bokov, A. F., Majumder, S., & Oddo, S. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012851108 · Cited by 249
Bihaqi, S. W., Huang, H., Wu, J., & Zawia, N. H. (2011) · Journal of Alzheimer’s Disease · doi:10.3233/jad-2011-111013 · Cited by 162 · cited 3×
“Developmental exposure to lead (Pb) upregulates genes involved in AD late in life through mechanisms that involve DNA methylation and histone acetylation (Wu et al., 2008a; Bihaqi et al., 2011; Bihaqi & Zawia, 2012).”
Self-citationSung, Y. M., Lee, T., Yoon, H., DiBattista, A. M., Song, J. M., Sohn, Y., Moffat, E. I., Turner, R. S., Jung, M., Kim, J., et al. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2012.10.005 · Cited by 152
DNA methylation impacts on learning and memory in aging
Liu, L., van Groen, T., Kadish, I., & Tollefsbol, T. O. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.07.020 · Cited by 152 · cited 6×
“When studying DNAmethylation within the cerebral cortex of AD and control subjects, two out of the fifty loci examined were differentially methylated in AD which represent an acceleration of aging-linked alterations (Siegmund et al., 2007).”
InfluentialHistone modifications, DNA methylation, and Schizophrenia
Gavin, D. P., & Sharma, R. P. (2010) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2009.10.010 · Cited by 121
Epigenetic mechanisms in stress and adaptation
Mifsud, K. R., Gutièrrez-Mecinas, M., Trollope, A. F., Collins, A., Saunderson, E. A., & Reul, J. M. H. M. (2011) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2011.06.005 · Cited by 100 · cited 2×
“…and stress (Shahbazian & Zoghbi, 2002; Jaenisch & Bird, 2003; Zawia et al., 2009; Nguyen et al., 2010; Qureshi & Mehler, 2010; Maze & Nestler, 2011; Mifsud et al., 2011; Taqi et al., 2011; Heim & Binder, 2012; Kreth et al., in press; Maric & Svrakic, 2012; Orr et al., 2012; Inkster et al., 2013).”
Dosunmu, R., Alashwal, H., & Zawia, N. H. (2012) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2012.05.003 · Cited by 91 · cited 1×
“Persistent bidirectional changes in DNA methylation in response to earlier Pb exposure are reported with hypermethylation resulting in a latent reduction in gene expression (Alashwal et al., 2012; Dosunmu et al., 2012).”
Self-citationChouliaras, L., L.A. van den Hove, D., Kenis, G., Keitel, S., R. Hof, P., van Os, J., W.M. Steinbusch, H., Schmitz, C., & P.F. Rutten, B. (2012) · Current Alzheimer Research · doi:10.2174/156720512800618035 · Cited by 91
Caloric restriction attenuates age-related changes of DNA methyltransferase 3a in mouse hippocampus
Chouliaras, L., van den Hove, D. L. A., Kenis, G., Dela Cruz, J., Lemmens, M. A. M., van Os, J., Steinbusch, H. W. M., Schmitz, C., & Rutten, B. P. F. (2011) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2010.11.016 · Cited by 89 · cited 4×
“Such epigenetic changes could be prevented by 50% caloric restriction diet throughout the mice lifetime after weaning (Chouliaras et al., 2011; Chouliaras et al., 2012a; Chouliaras et al., 2012b).”
InfluentialTucker, S., Ahl, M., Cho, H.-H., Bandyopadhyay, S., Cuny, G., Bush, A., Goldstein, L., Westaway, D., Huang, X., & Rogers, J. (2006) · Current Alzheimer Research · doi:10.2174/156720506777632835 · Cited by 62 · cited 2×
“Targeting non-coding RNA regions on APP by the antibiotic erythromycin, the antidepressant paroxetine andN-acetyl cysteine has been found to reduce Aβ in TgCRND8 transgenicmice (Tucker et al., 2005; Tucker et al., 2006).”
Levkovitz, Y., Alpert, J. E., Brintz, C. E., Mischoulon, D., & Papakostas, G. I. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.04.059 · Cited by 51
Koseki, T., Mouri, A., Mamiya, T., Aoyama, Y., Toriumi, K., Suzuki, S., Nakajima, A., Yamada, T., Nagai, T., & Nabeshima, T. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001672 · Cited by 44 · cited 1×
“Sodium butyrate also protects against phencyclidine induced psychotic-like behavior in mice (Koseki et al., 2012).”
Cited by
The epigenetics of aging and neurodegeneration
Lardenoije, R., Iatrou, A., Kenis, G., Kompotis, K., Steinbusch, H. W. M., Mastroeni, D., Coleman, P., Lemere, C. A., Hof, P. R., van den Hove, D. L. A., et al. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.05.002 · Cited by 381
“The epigenetic machinery covers multiple levels of control, including DNA methylation and hydroxymethylation, chromatin remodeling, and non-coding RNA (ncRNA) regulation (Adwan and Zawia, 2013).”
BackgroundOlive Polyphenols: Antioxidant and Anti-Inflammatory Properties
Bucciantini, M., Leri, M., Nardiello, P., Casamenti, F., & Stefani, M. (2021) · Antioxidants · doi:10.3390/antiox10071044 · Cited by 301
Rigacci, S., & Stefani, M. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17060843 · Cited by 290
Monoaminergic neuropathology in Alzheimer’s disease
Šimić, G., Babić Leko, M., Wray, S., Harrington, C. R., Delalle, I., Jovanov-Milošević, N., Bažadona, D., Buée, L., de Silva, R., Di Giovanni, G., et al. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.04.001 · Cited by 289
Epigenetic mechanisms of major depression: Targeting neuronal plasticity
Uchida, S., Yamagata, H., Seki, T., & Watanabe, Y. (2018) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12621 · Cited by 181
Metadata
- Authors
- Adwan, L., & Zawia, N. H.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2013-07
- Volume
- 139
- Issue
- 1
- Pages
- 41-50
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W2098633756
- Cited by
- 115
- References
- 73
- FWCI
- 11.63
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.